Brokerages Set Agenus Inc. (NASDAQ:AGEN) Target Price at $10.00

Shares of Agenus Inc. (NASDAQ:AGEN) have been assigned an average rating of “Hold” from the six research firms that are covering the firm, Marketbeat reports. Five investment analysts have rated the stock with a hold recommendation and one has given a buy recommendation to the company. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $10.00.

AGEN has been the topic of several analyst reports. HC Wainwright cut their target price on Agenus from $8.00 to $7.00 and set a “neutral” rating on the stock in a research note on Tuesday, November 12th. B. Riley cut their price target on shares of Agenus from $42.00 to $18.00 and set a “buy” rating on the stock in a research report on Wednesday, August 14th. Finally, StockNews.com lowered shares of Agenus from a “hold” rating to a “sell” rating in a research note on Monday, August 12th.

Agenus Stock Up 16.8 %

AGEN stock opened at $3.34 on Thursday. Agenus has a twelve month low of $2.50 and a twelve month high of $19.69. The business’s fifty day moving average is $4.41 and its 200-day moving average is $8.33. The company has a market cap of $78.36 million, a P/E ratio of -0.30 and a beta of 1.39.

Institutional Investors Weigh In On Agenus

A number of hedge funds have recently modified their holdings of AGEN. BNP Paribas Financial Markets grew its position in shares of Agenus by 81.3% in the 1st quarter. BNP Paribas Financial Markets now owns 188,414 shares of the biotechnology company’s stock valued at $109,000 after purchasing an additional 84,477 shares during the period. Vanguard Group Inc. boosted its holdings in shares of Agenus by 13.7% in the first quarter. Vanguard Group Inc. now owns 34,401,122 shares of the biotechnology company’s stock valued at $19,953,000 after buying an additional 4,134,232 shares during the period. Acadian Asset Management LLC increased its position in shares of Agenus by 1,959.9% during the first quarter. Acadian Asset Management LLC now owns 757,397 shares of the biotechnology company’s stock worth $439,000 after acquiring an additional 720,629 shares in the last quarter. Price T Rowe Associates Inc. MD raised its holdings in shares of Agenus by 52.4% during the first quarter. Price T Rowe Associates Inc. MD now owns 357,915 shares of the biotechnology company’s stock worth $208,000 after acquiring an additional 123,058 shares during the period. Finally, Ovata Capital Management Ltd bought a new stake in Agenus in the 2nd quarter valued at $670,000. Institutional investors and hedge funds own 61.46% of the company’s stock.

About Agenus

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.